Skip to contentA
Arcus Biosciences, Inc.
A
RCUSArcus Biosciences, Inc. Q4 2020 · 10-K
Revenue$9.49M$9.49M−2.7% vs Q4 2019 Net Income-$51.85M-$51.85MN/M vs Q4 2019 EPS Diluted-$0.82-$0.82no prior Q4 2019 on file Operating Incomederived-$51,777,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
Operating Cash Flowderived-$50,050,000N/M Free Cash Flowderived-$51,514,000N/M Margins · derivedOperating margin-545.8%−366.0 pt vs Q4 2019
Net margin-546.6%−376.3 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end